http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
비소세포성 폐암에서 Gefitinib과 삼칠충초정을 병용 투약하여 약물 내성이 연장된 1례
고명현 ( Myung-hyun Ko ),반경태 ( Gyung-tae Ban ),박소정 ( So-jung Park ),박지혜 ( Ji-hye Park ),이연월 ( Yeon-weol Lee ),조정효 ( Jung-hyo Cho ),유화승 ( Hwa-seung Yoo ) 대전대학교 한의학연구소 2021 혜화의학회지 Vol.30 No.2
Objective : The purpose of this study was to report the case of prolonged drug resistance non-small cell lung cancer (NSCLC) with Samchilchoongcho-Jung (HAD-B1) in combining with Gefitinib. Methods : The patient was diagnosed with Epidermal Growth Factor Receptor mutation (EGFR) NSCLC adenocarcinoma. The patient being treated with Gefitinib was treated with HAD-B1 for prolonged drug resistance. The clinical outcomes were measured by Response Evaluation Criteria in Solid Tumors (RECIST), National Cancer Institute Common Terminology Criteria for Adverse Event (NCI -CTCAE), laboratory findings, etc. Results : After combining treatment, the drug resistance of Gefitinib was prolonged about 20 months. The tumor marker levels were also maintained. NCI-CTCAE 6.0 showed no adverse events. Conclusion: This case study suggested that HAD-B1 may prolong the drug resistance of Gefitinib.